EDISON, N.J., Dec. 15 /PRNewswire/ -- The Musculoskeletal Transplant Foundation (MTF) announced today that it has completed a major portion of the development phase in its efforts to develop a next-generation stem cell allograft tissue form in partnership with Orthofix International N.V. (Nasdaq: OFIX). MTF's research team has delivered a robust data package to Orthofix which confirms the relative superiority of this tissue form against other similar tissue forms already on the market. The partnership between MTF and Orthofix has now achieved success in the development phase, allowing the quick transition to commercialization and an expectation that the tissue form will be available to surgeons by June 2009.
"Our partnership with Orthofix is an excellent example of how the non-profit and for-profit worlds can work together to pursue medical advances that will significantly benefit patients," said Bruce Stroever, CEO of MTF. "Our team is very pleased to have achieved this major development milestone, knowing that it means surgeons will have a next-generation stem cell-based allograft available for use within six months."
In 2008, MTF and Orthofix announced a Development Agreement to work together to develop and distribute a stem cell-based allograft tissue form. The new tissue form, called Trinity Evolution(TM), will bring advances to the surgical use of allografts. The tissue form is a stem cell-based bone growth matrix designed to behave like an autograft in spinal and orthopedic surgeries.
In addition to its research and development expertise, MTF acts as a bridge between the donor, the donor family and the transplant recipient; processing and distributing allograft tissue to hospitals and clinics around the country. As a non-profit service organization, MTF provides quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families.
"The Musculoskeletal Transplant Foundation is a world leader in tissue research and development, and we knew that together we could make great advances in medical science," said Alan Milinazzo, CEO of Orthofix. "The commercialization of Trinity Evolution(TM) will provide surgeons and their patients with an exciting new stem cell-based tissue form for use in surgical bone grafting procedures."
With the completion of this major development milestone, MTF will now turn its focus to producing the allograft and preparing for a commercial launch with Orthofix by June of 2009.
About The Musculoskeletal Transplant Foundation
The Musculoskeletal Transplant Foundation is the nation's largest full service tissue organization dedicated to providing quality tissue through a commitment to excellence in education, research, recovery and care for recipients, donors and their families. A not-for-profit organization, MTF is a consortium of academic medical institutions and organ and tissue recovery organizations across the country. In its first 20 years, MTF and its recovery partners have recovered over 60,000 donors and provided over three million tissue grafts to patients in need. For more information, please visit MTF's website at www.mtf.org.
Orthofix International N.V., a global diversified orthopedic products
company, offers a broad line of minimally invasive surgical, and non-surgical,
products for the spine, orthopedic, and sports medicine market sectors that
address the lifelong bone and joint health needs of patients of all ages,
helping them achieve a more active and mobile lifestyle. Orthofix's products
are widely distributed around the world to orthopedic surgeons and patients
via Orthofix's sales representatives and its subsidiaries, including BREG,
Inc. and Blackstone Medical, Inc., and via partnerships with other leading
orthopedic product companies. In addition, Orthofix is collaborating in R&D
partnerships with leading medical institutions such as the Orthopedic Research
and Education Foundation,
|SOURCE Musculoskeletal Transplant Foundation|
Copyright©2008 PR Newswire.
All rights reserved